Abel

Abel-80 (Azilsartan Medoxomil) has an antihypertensive effect, and belongs to the class of angiotensin II receptor antagonists (AT1 subtype).

Blocking of AT1 receptors results in inhibition of the negative angiotensin II negative effect on renin secretion, but increased plasma renin activity and elevated angiotensin II levels in the systemic bloodstream resulting from receptor blockage do not interfere with the development of hypotension.

The drug is used to treat essential arterial hypertension that is not treatable with lower doses.

Always follow your doctor`s instructions when using Abel-80 (Azilsartan Medoxomil) to get the safest and most effective results from treatment. The recommended dose is 80 mg once a day.

Abel-80 (Azilsartan Medoxomil) should be taken daily, without interruption.

If treatment is discontinued, the patient should inform the doctor.

Skip dose. If you missed the dose, you should take the next dose at the usual time. Do not take a double dose of Abel-80 (Azilsartan Medoxomil).

The use of Abel-80 (Azilsartan Medoxomil) may cause side effects in some patients including:

• hypotension
• dizziness
• rash, itching
• diarrhea
• nausea
• muscle spasms
• fatigue
• peripheral edema
• increase of level of uric acid in blood

Contact your doctor immediately if you experience any serious or worrying symptoms.

Due to the lack of controlled epidemiological data on the risk associated with angiotensin II receptor blockers, this risk cannot be ruled out for this class of drugs. If continued therapy with angiotensin II receptor blockers is not compulsory, patients planning pregnancy should switch to alternative antihypertensive therapy that has a better safety profile for use by pregnant women.

Angiotensin II receptor blocker therapy in women in the 2nd and 3rd trimesters of pregnancy can lead to fetotoxicity (decreased renal function, delayed ossification of skull bones) and neonatal toxicity (renal failure).

Azilsartan medoxomil is not recommended for use in breastfeeding due to lack of appropriate data.

Azilsartan medoxomil does not or may have a minor effect on the reaction rate when driving or operating with other mechanisms. However, you should be aware of the possible occurrence of dizziness or fatigue.